Key points are not available for this paper at this time.
T细胞在控制多种人类癌症中的临床相关性现已毋庸置疑。然而,使免疫系统能够区分癌细胞与非癌细胞的抗原性质长期以来一直不明朗。近期的技术创新使得解析针对由肿瘤特异性突变产生的患者特异性新抗原的免疫反应成为可能,最新数据表明,识别此类新抗原是临床免疫疗法疗效的关键因素。这些观察表明,新抗原负荷可能成为癌症免疫治疗中的生物标志物,并为开发选择性增强针对这类抗原的T细胞反应的新疗法提供了动力。
Building similarity graph...
Analyzing shared references across papers
Loading...
Ton N. Schumacher
Robert D. Schreiber
Science
Washington University in St. Louis
The Netherlands Cancer Institute
Building similarity graph...
Analyzing shared references across papers
Loading...
Schumacher等人(周四)研究了这个问题。
www.synapsesocial.com/papers/699562c47d03e66a93cf9e92 — DOI: https://doi.org/10.1126/science.aaa4971
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: